Home LiteratureArticle Details
PMID: 11264394 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Journal of virology ·Vol. 75 ·No. 8 ·2001-04-00 ·Pages 4014-8

Chazal N, Singer G, Aiken C, Hammarskjöld ML, Rekosh D

Abstract

We have investigated the effects of Nef on infectivity in the context of various viral envelope proteins. These experiments were performed with a minimal vector system where Nef is the only accessory protein present. Our results support the hypothesis that the route of entry influences the ability of Nef to enhance human immunodeficiency virus (HIV) infectivity. We show that HIV particles pseudotyped with Ebola virus glycoprotein or vesicular stomatitis virus glycoprotein (VSV-G), which fuse at low pH, do not require Nef for optimal infectivity. In contrast, Nef significantly enhances the infectivity of virus particles that contain envelope proteins that fuse at neutral pH (CCR5-dependent HIV Env, CXCR4-dependent HIV Env, or amphotropic murine leukemia virus Env). In addition, our results demonstrate that virus particles containing mixed CXCR4-dependent HIV and VSV-G envelope proteins show a conditional requirement for Nef for optimal infectivity, depending on which protein is allowed to facilitate entry.

MeSH Terms
Animals Anti-Bacterial Agents/pharmacology Antibodies, Viral/immunology Cell Line Gene Deletion Gene Products, nef/genetics,metabolism HIV Envelope Protein gp120/genetics,immunology,metabolism HIV-1/genetics,immunology,metabolism,pathogenicity HeLa Cells Humans Hydrogen-Ion Concentration Immune Sera/immunology Macrolides Membrane Fusion Membrane Glycoproteins Molecular Sequence Data Neutralization Tests Receptors, HIV/genetics,metabolism Viral Envelope Proteins/genetics,immunology,metabolism nef Gene Products, Human Immunodeficiency Virus
Chemicals
Anti-Bacterial Agents Antibodies, Viral G protein, vesicular stomatitis virus Gene Products, nef HIV Envelope Protein gp120 Immune Sera Macrolides Membrane Glycoproteins Receptors, HIV Viral Envelope Proteins envelope glycoprotein, Ebola virus nef Gene Products, Human Immunodeficiency Virus bafilomycin A1
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Chazal N
Myles H. Thaler Center for AIDS and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia 22908, USA.
Singer G
Aiken C
Hammarskjöld M L
Rekosh D
References (39)
39 references, click to expand
  1. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses.
    J Virol. 2000 May;74(10):4933-7 PMID: 10775638
  2. Association of Nef with the human immunodeficiency virus type 1 core.
    J Virol. 1999 Oct;73(10):8824-30 PMID: 10482638
  3. Pathway of vesicular stomatitis virus entry leading to infection.
    J Mol Biol. 1982 Apr 15;156(3):609-31 PMID: 6288961
  4. Vesicular stomatitis virus binds and fuses with phospholipid domain in target cell membranes.
    Biochemistry. 1986 Jun 17;25(12):3703-8 PMID: 3013294
  5. New host cell system for regulated simian virus 40 DNA replication.
    Mol Cell Biol. 1985 Nov;5(11):3231-40 PMID: 3018509
  6. pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane.
    Cell. 1987 Jun 5;49(5):659-68 PMID: 3107838
  7. Human immunodeficiency virus infection of T cells and monocytes proceeds via receptor-mediated endocytosis.
    J Cell Biol. 1988 Sep;107(3):959-68 PMID: 3262112
  8. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells.
    Proc Natl Acad Sci U S A. 1988 Nov;85(21):7972-6 PMID: 2973058
  9. A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site.
    Cell. 1990 Mar 9;60(5):747-54 PMID: 2107024
  10. Identification of a cis-acting element in human immunodeficiency virus type 2 (HIV-2) that is responsive to the HIV-1 rev and human T-cell leukemia virus types I and II rex proteins.
    J Virol. 1990 Apr;64(4):1690-7 PMID: 2157051
  11. The pH independence of mammalian retrovirus infection.
    J Gen Virol. 1990 Apr;71 ( Pt 4):767-73 PMID: 2157795
  12. HIV: early virus-cell interactions.
    J Acquir Immune Defic Syndr. 1990;3(10):965-74 PMID: 2398460
  13. The cytotoxic action of diphtheria toxin and its degradation in intact Vero cells are inhibited by bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase.
    J Biol Chem. 1990 Dec 15;265(35):21940-5 PMID: 2147689
  14. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.
    J Virol. 1991 Jan;65(1):162-9 PMID: 1845882
  15. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.
    J Biol Chem. 1991 Sep 15;266(26):17707-12 PMID: 1832676
  16. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.
    J Virol. 1992 Apr;66(4):2232-9 PMID: 1548759
  17. Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles.
    J Virol. 1993 May;67(5):2681-8 PMID: 8474168
  18. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages.
    J Exp Med. 1994 Jan 1;179(1):101-13 PMID: 8270859
  19. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene.
    J Virol. 1994 May;68(5):2906-14 PMID: 8151761
  20. The HIV-1 nef gene acts as a positive viral infectivity factor.
    Trends Microbiol. 1994 Aug;2(8):294-8 PMID: 7981973
  21. Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry.
    J Virol. 1995 Jan;69(1):579-84 PMID: 7983759
  22. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell.
    J Virol. 1995 Jul;69(7):4053-9 PMID: 7539505
  23. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis.
    J Virol. 1995 Aug;69(8):5048-56 PMID: 7541845
  24. The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation.
    Virology. 1995 Oct 1;212(2):451-7 PMID: 7571414
  25. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
    Science. 1996 Apr 12;272(5259):263-7 PMID: 8602510
  26. Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase.
    Virology. 1996 May 1;219(1):228-36 PMID: 8623533
  27. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
    Science. 1996 May 10;272(5263):872-7 PMID: 8629022
  28. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein.
    J Virol. 1996 Jul;70(7):4283-90 PMID: 8676450
  29. Identification of a major co-receptor for primary isolates of HIV-1.
    Nature. 1996 Jun 20;381(6584):661-6 PMID: 8649511
  30. Chemokine receptors and HIV-1: an attractive pair?
    Cell. 1996 Jul 12;86(1):1-3 PMID: 8689676
  31. Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease.
    J Virol. 1997 Feb;71(2):1013-8 PMID: 8995620
  32. SFV infection in CHO cells: cell-type specific restrictions to productive virus entry at the cell surface.
    J Cell Sci. 1997 Jan;110 ( Pt 1):95-103 PMID: 9010788
  33. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.
    J Virol. 1997 Aug;71(8):5841-8 PMID: 9223473
  34. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.
    J Virol. 1997 Aug;71(8):5871-7 PMID: 9223476
  35. Immunization for Ebola virus infection.
    Nat Med. 1998 Jan;4(1):37-42 PMID: 9427604
  36. Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins.
    Science. 1998 Feb 13;279(5353):1034-7 PMID: 9461435
  37. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems.
    Virology. 1998 Feb 15;241(2):224-33 PMID: 9499797
  38. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines.
    J Virol. 1998 Apr;72(4):3155-60 PMID: 9525641
  39. Endocytic entry of HIV-1.
    Curr Biol. 2000 Aug 24;10(16):1005-8 PMID: 10985390
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.75.8.4014-4018.2001
Published
2001-04-00
Pages
4014-8
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC114896
Subset
IM
Grants
NIAID NIH HHS · R01 AI040364 · United States
NIAID NIH HHS · AI 40364 · United States
NIAID NIH HHS · AI38186 · United States
NIAID NIH HHS · AI44349 · United States
Databases
GENBANK
M38429
External Links
PubMed source DOI: 10.1128/JVI.75.8.4014-4018.2001 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2